Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & Administrative
Others
Ratios

Molecular Partners Ag (MOLN) EBITDA (2021 - 2025)

Historic EBITDA for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to -$15057.1.

  • Molecular Partners Ag's EBITDA rose 1058.03% to -$15057.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $19891.0, marking a year-over-year increase of 10000.01%. This contributed to the annual value of -$69.57 for FY2024, which is 20099.41% down from last year.
  • According to the latest figures from Q3 2025, Molecular Partners Ag's EBITDA is -$15057.1, which was up 1058.03% from -$20.92 recorded in Q2 2025.
  • Molecular Partners Ag's EBITDA's 5-year high stood at $165.2 billion during Q1 2022, with a 5-year trough of -$18.2 billion in Q1 2024.
  • Moreover, its 5-year median value for EBITDA was -$16838.7 (2024), whereas its average is $8.9 billion.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 80597508206.4% in 2022, then plummeted by 17035.12% in 2023.
  • Over the past 5 years, Molecular Partners Ag's EBITDA (Quarter) stood at $51.7 billion in 2021, then plummeted by 99.77% to $120.9 million in 2022, then crashed by 99.96% to $50191.1 in 2023, then rose by 5.44% to $52923.0 in 2024, then tumbled by 128.45% to -$15057.1 in 2025.
  • Its EBITDA stands at -$15057.1 for Q3 2025, versus -$20.92 for Q2 2025 and -$17953.9 for Q1 2025.